Michael Kneba

47.1k total citations · 1 hit paper
216 papers, 8.1k citations indexed

About

Michael Kneba is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Michael Kneba has authored 216 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Genetics, 119 papers in Pathology and Forensic Medicine and 61 papers in Immunology. Recurrent topics in Michael Kneba's work include Chronic Lymphocytic Leukemia Research (122 papers), Lymphoma Diagnosis and Treatment (119 papers) and Immunodeficiency and Autoimmune Disorders (43 papers). Michael Kneba is often cited by papers focused on Chronic Lymphocytic Leukemia Research (122 papers), Lymphoma Diagnosis and Treatment (119 papers) and Immunodeficiency and Autoimmune Disorders (43 papers). Michael Kneba collaborates with scholars based in Germany, Netherlands and United States. Michael Kneba's co-authors include Matthias Ritgen, Monika Brüggemann, Thorsten Raff, Christiane Pott, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer, Sebastian Böttcher, Nicola Gökbuget and Dieter Hoelzer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Michael Kneba

204 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology

2006 653 citations Michael Kneba et al. profile →

Peers

Countries citing papers authored by Michael Kneba

Since Specialization

Citations

This map shows the geographic impact of Michael Kneba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kneba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kneba more than expected).

Fields of papers citing papers by Michael Kneba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kneba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kneba. The network helps show where Michael Kneba may publish in the future.

Co-authorship network of co-authors of Michael Kneba

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Kneba. A scholar is included among the top collaborators of Michael Kneba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Kneba. Michael Kneba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis 2022 ·Cancers ·Anke Schilhabel, (unknown), Paula Cramer, Julia von Tresckow, (unknown), Monika Szczepanowski, (unknown), Kirsten Fischer, Barbara Eichhorst, Sebastian Böttcher, Christof Schneider, Eugen Tausch, Monika Brüggemann, Michael Kneba, Michael Hallek, Matthias Ritgen	3
2	CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia - Results of the GMALL 08/2013 Trial 2018 ·Blood ·Monika Szczepanowski, Johanna Richter, (unknown), Matthias Ritgen, Heiko Trautmann, Henrik Knecht, Mustafa Kondakci, Christoph Faul, Björn Steffen, Andreas Viardot, Michael Kneba, Dieter Hoelzer, Nicola Goekbuget, Monika Brüggemann	3
3	Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients 2018 ·Blood ·Christiane Pott, Eva Hoster, (unknown), Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiřı́ Mayer, Christopher Pocock, Andrea Knapp, (unknown), Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann	20
4	Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy 2017 ·Blood ·Inga Nagel, Marius Bartels, Johannes Duell, Hans‐Heinrich Oberg, Sandra Ussat, Henrike Bruckmueller, Oliver G. Ottmann, Roman Pfeifer, Heiko Trautmann, Nicola Gökbuget, Almuth Caliebe, Dieter Kabelitz, Michael Kneba, Heinz‐August Horst, Dieter Hoelzer, Max S. Topp, Ingolf Cascorbi, Reiner Siebert, Monika Brüggemann	63
5	Standardized IGH-Based Next-Generation Sequencing for MRD Detection in Follicular Lymphoma 2017 ·Blood ·Christiane Pott, Henrik Knecht, (unknown), Elisa Genuardi, Michael Unterhalt, Barbara Mantoan, Irene Dogliotti, Wolfgang Hiddemann, Mario Boccadoro, Dietrich Herrmann, Michael Kneba, Anton W. Langerak, Nikos Darzentas, Patricia J.T.A. Groenen, Monika Brüggemann, Eva Hoster, Marco Ladetto, Simone Ferrero	7
6	Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study 2017 ·Annals of Oncology ·Beate Schultheis, Dirk Reuter, M. Ebert, Jens T. Siveke, Andrea Kerkhoff, Wolfgang E. Berdel, Ralf‐Dieter Hofheinz, Dirk Behringer, Wolfgang E. Schmidt, Erdem Göker, Sara De Dosso, Michael Kneba, Şuayib Yalçın, Friedrich Overkamp, Frank Schlegel, (unknown), Robert Rohrberg, (unknown), Michael Bulitta, Dirk Strumberg	97
7	GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses 2016 ·Bone Marrow Transplantation ·Leopold Sellner, Monika Brüggemann, (unknown), Henrik Knecht, D. Herrmann, Tomáš Reigl, Adam Krejčí, Vojtěch Bystrý, Nikos Darzentas, Michael A. Rieger, Sascha Dietrich, Thomas Luft, Anthony D. Ho, Michael Kneba, Peter Dreger	25
8	Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1) 2013 ·Clinical Cancer Research ·Anne T. Nies, Elke Schaeffeler, Heiko van der Kuip, Ingolf Cascorbi, Oliver Bruhn, Michael Kneba, Christiane Pott, Ute Hofmann, Christopher Volk, Shuiying Hu, Sharyn D. Baker, Alex Sparreboom, Peter Ruth, Hermann Koepsell, Matthias Schwab	52
9	Evaluation of minimal residual disease in chronic lymphocytic leukemia 2009 ·Matthias Ritgen, Sebastian Böttcher, Peter Dreger, Michael Kneba	0
10	Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma 2009 ·Haematologica ·Inga Nagel, Takashi Akasaka, Wolfram Klapper, Stefan Gesk, Sebastian Böttcher, Matthias Ritgen, Lana Harder, Michael Kneba, Martin J.S. Dyer, Reiner Siebert	15
11	Reduced expression of C1q-mRNA in monocytes from patients with systemic lupus erythematosus 2006 ·Clinical & Experimental Immunology ·Frank Moosig, Frédérik Damm, (unknown), Matthias Ritgen, Rainald Zeuner, Michael Kneba, Martin Ernst, Johann O. Schröder	24
12	Successful autologous stem cell transplantation in a severely immunocompromised patient with relapsed AIDS-related B-cell lymphoma. 2006 ·PubMed ·Christian Hoffmann, Roland Repp, Robert Schoch, B. Gahn, Natalie Schub, Christopher A. Beck, Andreas Humpe, Michael Kneba, H. -A. Horst, Norbert Schmitz, Martin Gramatzki	3
13	Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease 2005 ·European Journal Of Haematology ·Christiane Pott, Carsten Schrader, Monika Brüggemann, Matthias Ritgen, Lana Harder, Thorsten Raff, Markus Tiemann, Peter Dreger, Michael Kneba	17
14	Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) 2004 ·Leukemia ·C.‐M. Wendtner, Matthias Ritgen, (unknown), Guenter Fingerle-Rowson, Hartmut Campe, Gundula Jäger, Barbara Eichhorst, Robert Busch, Heinz Diem, Andreas Engert, Stephan Stilgenbauer, Hartmut Döhner, Michael Kneba, Bertold Emmerich, Michael Hallek, (unknown)	201
15	Fludarabine induces higher response rates in first line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil Interim analysis of a phase III study of the German CLL Study Group 2003 ·Blood ·Barbara Eichhorst, Raymonde Busch, Martina Stauch, Michael Kneba, Matthias Ritgen, (unknown), Oswald Burkhard, Michael Bergmann, Clemens‐Martin Wendtner, Wolfgang Hiddemann, Bertold Emmerich, Michael Hallek, (unknown)	9
16	The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL) - Results of a prospective randomized comparison of the German low grade study group (GLSG). 2001 ·Data Archiving and Networked Services (DANS) ·(unknown), Roswitha Forstpointner, F. Fiedler, Martin Gramatzki, Bernd Dörken, (unknown), Michael Kneba, M. Pfreundschuh, (unknown), (unknown), Martin Dreyling, (unknown)	0
17	Improvement of Hammerhead Ribozymes Cleavingmdr-1mRNA 1995 ·Biological Chemistry Hoppe-Seyler ·(unknown), Michael Kneba, Wolfgang Hiddemann, J. Bertram	11
18	Comparison of 5 vs 10 μg/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer 1993 ·Annals of Hematology ·Carsten Bokemeyer, Hans‐Joachim Schmoll, Bernd Metzner, J. Beyer, H. J. Illiger, Michael Kneba, Helmut Ostermann, B. Kynast, U. Räth, H. Poliwoda	7
19	A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours 1993 ·European Journal of Cancer ·C. Bokemeyer, Hans‐Joachim Schmoll, A. Harstrick, H. J. Illiger, Bernd Metzner, U. Räth, (unknown), C. Clemm, Wolfgang E. Berdel, W. Siegert, U. Rüther, Helmut Ostermann, Michael Kneba, J. Hartlapp, (unknown), H. Poliwoda	21
20	Sequence analysis of amplified t(14;18) chromosomal breakpoints in B‐cell lymphomas 1990 ·The Journal of Pathology ·(unknown), G. Krieger, I Bolz, Michael Kneba	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact